The prescribed dosage for Rezdiffra (resmetirom) may depend on a person’s individual treatment plan. Factors like your medical history and body weight may affect your dosage of Rezdiffra.

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH).

Rezdiffra is not approved for the treatment of patients with MASH cirrhosis. Concurrently, Madrigal Pharmaceuticals reported a fourth-quarter loss of $2.71 per share, down from a loss of $5.68 a ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH). As the ...

Rezdiffra reduced liver stiffness by 6.7 kPa at two years, with 51% of patients showing ≥25% improvement in MASH cirrhosis. Madrigal posted a Q4 loss of $2.71 per share, beating estimates ...

By the end of last year, more than 11,800 patients were on Rezdiffra. In a conference call on Wednesday, Madrigal CEO Bill Sibold called the progress “an incredible accomplishment in just nine ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

The safety and tolerability profile of Rezdiffra in the trial was consistent with previous studies, showing a low rate of discontinuations due to adverse events. Madrigal plans to present ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash ...

On Wednesday, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra ...